Phase 2 N=135 Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery
Surgical Adhesions
Primary: TAM2 — 108; 121 Degrees — p=0.8861
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=648 The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay (Using Human Complement) (hSBA) Titers Equal to or Above the Cut-off Values — 102; 35; 15; 319 Subjects
Phase 2 N=134 Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
Dentine Hypersensitivity
Primary: Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4 — -0.36; -0.43; -0.40; -0.45 Score on a scale — p=0.4553
Phase 2 N=44 S0916, MLN1202 in Treating Patients With Bone Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: uNTX Response Rate at 43 Days — 14 percentage of participants
Phase 2 N=31 Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Non Insulin Dependent Diabetes · Pregnancy
Primary: Blood Glucose Measurements — 97.38; 95.04; 97.00; 92.38 mg/dL
Phase 2 N=332 Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24) — 90.4; 92.7; 91.0; 93.3 percentage of participants…
Phase 2 N=31 Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Recurrent Breast Carcinoma · Stage III Breast Cancer AJCC v7 · Stage IIIA Breast Cancer AJCC v7
Primary: Clinical Benefit Rate (Complete Response, Partial Response, or Stable Disease) — 9.7 percentage of participants
Phase 2 N=110 A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Disease, Hodgkin · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate by Investigator — 60; 91; 33; 68 percentage of retreatment experiences
Phase 2 N=213 Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Carcinoma, Renal Cell
Primary: Objective Response Rate (ORR) - Percentage of Participants With Objective Response — 53.6; 33.9; 59.3; 48.4 Percentage of Participants — p=0.0189
Phase 2 N=29 Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion of Patients Who do Not Demonstrate Disease Progression
Phase 2 N=103 Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
Prostate Cancer
Primary: Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d). — 4.24; 4.23 log(ng*day/mL)
Phase 2 N=84 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 0; 0 participants
Phase 2 N=130 An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (INV) — 11.7; 11.4 Weeks — p=0.5197
Phase 2 N=152 Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Cancer · Head and Neck Cancer · Oncology
Primary: Local Regional Control Rate at 2 Years — 0.51; 0.61 Proportion of Participants
Phase 2 N=48 Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 21; 25 participants